Therapeutic Advances in Malignant Glioma: Current Status and Future Prospects Journal Article


Authors: Robins, H. I.; Lassman, A. B.; Khuntia, D.
Article Title: Therapeutic Advances in Malignant Glioma: Current Status and Future Prospects
Abstract: This article reviews the current status and trends in the treatment of primary gliomas, focusing predominantly on glioblastoma. It also discusses the current standard of care and new targeted agents currently under investigation. Furthermore, the concepts of pseudoprogression and pseudoresponse are introduced, which are new imaging correlates that have significant impact on understanding of the disease.
Keywords: cancer chemotherapy; treatment response; clinical trial; disease course; fatigue; review; bevacizumab; erlotinib; drug efficacy; gastrointestinal hemorrhage; hypertension; hypophosphatemia; treatment planning; antineoplastic agents; drug targeting; cancer radiotherapy; temozolomide; positron emission tomography; recurrent cancer; glioma; brain neoplasms; cancer diagnosis; imatinib; multiple cycle treatment; bleeding; thrombocytopenia; radiotherapy; deep vein thrombosis; antineoplastic activity; vasculotropin inhibitor; carmustine; irinotecan; temsirolimus; lung embolism; thromboembolism; glioblastoma; gefitinib; aflibercept; cediranib; nuclear magnetic resonance spectroscopy; colon perforation; headache; intestine perforation; methylated dna protein cysteine methyltransferase; drug therapy; brain ischemia; wound dehiscence; brain hemorrhage; targeted agents; neurosurgical procedures; pseudoprogression; pseudoresponse; radiation sensitizers; mesenteric vein thrombosis
Journal Title: Neuroimaging Clinics of North America
Volume: 19
Issue: 4
ISSN: 1052-5149
Publisher: Elsevier Inc.  
Date Published: 2009-11-01
Start Page: 647
End Page: 656
Language: English
DOI: 10.1016/j.nic.2009.08.015
PUBMED: 19959010
PROVIDER: scopus
DOI/URL:
Notes: --- - "Export Date: 30 November 2010" - "CODEN: NCNAE" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Andrew Lassman
    111 Lassman